GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc. The company's drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma. It is also developing a Phase 1 clinical trial drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. It has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone240-243-1201
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$20,000.00
Profitability
Miscellaneous
Employees40
Next Earnings Date3/5/2019 (Estimated)
OptionableOptionable
GlycoMimetics (NASDAQ:GLYC) Frequently Asked Questions
What is GlycoMimetics' stock symbol?
GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."
How were GlycoMimetics' earnings last quarter?
GlycoMimetics Inc (NASDAQ:GLYC) released its earnings results on Friday, August, 10th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.08. View GlycoMimetics' Earnings History.
When is GlycoMimetics' next earnings date?
What price target have analysts set for GLYC?
4 brokers have issued twelve-month price targets for GlycoMimetics' stock. Their predictions range from $24.00 to $35.00. On average, they anticipate GlycoMimetics' stock price to reach $27.6667 in the next year. This suggests a possible upside of 136.1% from the stock's current price. View Analyst Price Targets for GlycoMimetics.
What is the consensus analysts' recommendation for GlycoMimetics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GlycoMimetics.
Has GlycoMimetics been receiving favorable news coverage?
News stories about GLYC stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. GlycoMimetics earned a media sentiment score of -1.1 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future.
Who are some of GlycoMimetics' key competitors?
Some companies that are related to GlycoMimetics include Insmed (INSM), Endocyte (ECYT), Enanta Pharmaceuticals (ENTA), Madrigal Pharmaceuticals (MDGL), Supernus Pharmaceuticals (SUPN), Xencor (XNCR), PTC Therapeutics (PTCT), The Medicines (MDCO), Biohaven Pharmaceutical (BHVN), Myokardia (MYOK), AnaptysBio (ANAB), Mallinckrodt (MNK), Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB) and Pacira Pharmaceuticals (PCRX).
What other stocks do shareholders of GlycoMimetics own?
Who are GlycoMimetics' key executives?
GlycoMimetics' management team includes the folowing people:
- Ms. Rachel K. King, Pres, CEO & Director (Age 60)
- Mr. Brian M. Hahn, CFO & Sec. (Age 45)
- Dr. John L. Magnani, Sr. VP of Research, Chief Scientific Officer & Director (Age 66)
- Dr. Helen M. Thackray, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 51)
- Mr. Henry Flanner, VP of Technical Operations
Who are GlycoMimetics' major shareholders?
GlycoMimetics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.60%), Jennison Associates LLC (3.30%), Dimensional Fund Advisors LP (1.43%), Northern Trust Corp (1.03%), Geode Capital Management LLC (0.96%) and Hudson Bay Capital Management LP (0.81%). Company insiders that own GlycoMimetics stock include Brian M Hahn, Helen M Thackray, John L Magnani and M James Barrett. View Institutional Ownership Trends for GlycoMimetics.
Which institutional investors are selling GlycoMimetics stock?
GLYC stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Weiss Multi Strategy Advisers LLC, Barclays PLC, United Services Automobile Association, MetLife Investment Advisors LLC, BlackRock Inc., Northern Trust Corp and WINTON GROUP Ltd. Company insiders that have sold GlycoMimetics company stock in the last year include Brian M Hahn, John L Magnani and M James Barrett. View Insider Buying and Selling for GlycoMimetics.
Which institutional investors are buying GlycoMimetics stock?
GLYC stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Hudson Bay Capital Management LP, Squarepoint Ops LLC, Geode Capital Management LLC, Citigroup Inc., Alps Advisors Inc., Millennium Management LLC and GSA Capital Partners LLP. View Insider Buying and Selling for GlycoMimetics.
How do I buy shares of GlycoMimetics?
Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GlycoMimetics' stock price today?
One share of GLYC stock can currently be purchased for approximately $11.72.
How big of a company is GlycoMimetics?
GlycoMimetics has a market capitalization of $505.60 million and generates $20,000.00 in revenue each year. The biotechnology company earns $-33,280,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. GlycoMimetics employs 40 workers across the globe.
What is GlycoMimetics' official website?
How can I contact GlycoMimetics?
GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]
MarketBeat Community Rating for GlycoMimetics (NASDAQ GLYC)
MarketBeat's community ratings are surveys of what our community members think about GlycoMimetics and other stocks. Vote "Outperform" if you believe GLYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLYC will underperform the S&P 500 over the long term. You may vote once every thirty days.
